Advertisement

Soluble ST2 and Galectin-3 in Heart Failure

Published:January 16, 2014DOI:https://doi.org/10.1016/j.cll.2013.11.009

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Januzzi Jr., J.L.
        Natriuretic peptides as biomarkers in heart failure.
        J Investig Med. 2013; 61: 950-955
        • Weinberg E.
        • Shimpo M.
        • De Keulenaer G.
        • et al.
        Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction.
        Circulation. 2002; 106: 2961-2966
        • Iwahana H.
        • Yanagisawa K.
        • Ito-Kosaka A.
        • et al.
        Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells.
        Eur J Biochem. 1999; 264: 397-406
        • Seki K.
        • Sanada S.
        • Kudinova A.Y.
        • et al.
        Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling.
        Circ Heart Fail. 2009; 2: 684-691
        • Sanada S.
        • Hakuno D.
        • Higgins L.J.
        • et al.
        IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.
        J Clin Invest. 2007; 117: 1538-1549
        • Bartunek J.
        • Delrue L.
        • Van Durme F.
        • et al.
        Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load.
        J Am Coll Cardiol. 2008; 52: 2166-2174
        • Dieplinger B.
        • Januzzi K.
        • Steinmair M.
        • et al.
        Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma — the Presage ST2 assay.
        Clin Chim Acta. 2009; 409: 33-40
        • Coglianese E.E.
        • Larson M.G.
        • Vasan R.S.
        • et al.
        Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study.
        Clin Chem. 2012; 58: 1673-1681
        • Wang T.J.
        • Wollert K.C.
        • Larson M.G.
        • et al.
        Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study.
        Circulation. 2012; 126: 1596-1604
        • Henry-Okafor Q.
        • Collins S.P.
        • Jenkins C.A.
        • et al.
        Soluble ST2 as a diagnostic and prognostic marker for acute heart failure syndromes.
        Open Biomark J. 2012; 2012: 1-8
        • Januzzi Jr., J.L.
        • Peacock W.F.
        • Maisel A.S.
        • et al.
        Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study.
        J Am Coll Cardiol. 2007; 50: 607-613
        • Martinez-Rumayor A.
        • Camargo C.A.
        • Green S.M.
        • et al.
        Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease.
        Am J Clin Pathol. 2008; 130: 578-584
        • Lassus J.
        • Gayat E.
        • Mueller C.
        • et al.
        Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study.
        Int J Cardiol. 2013; 168: 2186-2194
        • Rehman S.
        • Mueller T.
        • Januzzi Jr., J.L.
        Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure.
        J Am Coll Cardiol. 2008; 52: 1458-1465
        • Manzano-Fernandez S.
        • Mueller T.
        • Pascual-Figal D.
        • et al.
        Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction.
        Am J Cardiol. 2011; 107: 259-267
        • Shah R.V.
        • Chen-Tournoux A.A.
        • Picard M.H.
        • et al.
        Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea.
        Circ Heart Fail. 2009; 2: 311-319
        • Pascual-Figal D.A.
        • Manzano-Fernandez S.
        • Boronat M.
        • et al.
        Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure.
        Eur J Heart Fail. 2011; 13: 718-725
        • Mueller T.
        • Dieplinger B.
        • Gegenhuber A.
        • et al.
        Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure.
        Clin Chem. 2008; 54: 752-756
        • Manzano-Fernandez S.
        • Januzzi J.L.
        • Pastor-Perez F.J.
        • et al.
        Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure.
        Cardiology. 2012; 122: 158-166
        • Boisot S.
        • Beede J.
        • Isakson S.
        • et al.
        Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure.
        J Card Fail. 2008; 14: 732-738
        • Zilinski J.L.
        • Shah R.V.
        • Gaggin H.K.
        • et al.
        Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy.
        Crit Care. 2012; 16: R135
        • Daniels L.B.
        • Clopton P.
        • Iqbal N.
        • et al.
        Association of ST2 levels with cardiac structure and function and mortality in outpatients.
        Am Heart J. 2010; 160: 721-728
        • Ky B.
        • French B.
        • McCloskey K.
        • et al.
        High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure.
        Circ Heart Fail. 2011; 4: 180-187
        • Bayes-Genis A.
        • Pascual-Figal D.
        • Januzzi J.L.
        • et al.
        Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure.
        Rev Esp Cardiol. 2010; 63: 1171-1178
        • Broch K.
        • Ueland T.
        • Nymo S.H.
        • et al.
        Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology.
        Eur J Heart Fail. 2012; 14: 268-277
        • Bayes-Genis A.
        • de Antonio M.
        • Galan A.
        • et al.
        Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure.
        Eur J Heart Fail. 2012; 14: 32-38
        • Pascual-Figal D.A.
        • Ordonez-Llanos J.
        • Tornel P.L.
        • et al.
        Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction.
        J Am Coll Cardiol. 2009; 54: 2174-2179
        • Kohli P.
        • Bonaca M.P.
        • Kakkar R.
        • et al.
        Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial.
        Clin Chem. 2012; 58: 257-266
        • Sabatine M.S.
        • Morrow D.A.
        • Higgins L.J.
        • et al.
        Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction.
        Circulation. 2008; 117: 1936-1944
        • Weir R.A.
        • Miller A.M.
        • Murphy G.E.
        • et al.
        Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.
        J Am Coll Cardiol. 2010; 55: 243-250
        • Sharma U.C.
        • Pokharel S.
        • van Brakel T.J.
        • et al.
        Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.
        Circulation. 2004; 110: 3121-3128
        • Calvier L.
        • Miana M.
        • Reboul P.
        • et al.
        Galectin-3 mediates aldosterone-induced vascular fibrosis.
        Arterioscler Thromb Vasc Biol. 2013; 33: 67-75
        • Yu L.
        • Ruifrok W.P.
        • Meissner M.
        • et al.
        Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.
        Circ Heart Fail. 2013; 6: 107-117
        • Gruson D.
        • Ko G.
        Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases?.
        Clin Biochem. 2012; 45: 719-726
        • Ho J.E.
        • Liu C.
        • Lyass A.
        • et al.
        Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.
        J Am Coll Cardiol. 2012; 60: 1249-1256
        • van Kimmenade R.R.
        • Januzzi Jr., J.L.
        • Ellinor P.T.
        • et al.
        Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.
        J Am Coll Cardiol. 2006; 48: 1217-1224
        • Shah R.V.
        • Chen-Tournoux A.A.
        • Picard M.H.
        • et al.
        Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.
        Eur J Heart Fail. 2010; 12: 826-832
        • Lin Y.H.
        • Lin L.Y.
        • Wu Y.W.
        • et al.
        The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
        Clin Chim Acta. 2009; 409: 96-99
        • van der Velde A.R.
        • Gullestad L.
        • Ueland T.
        • et al.
        Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.
        Circ Heart Fail. 2013; 6: 219-226
        • Anand I.S.
        • Rector T.S.
        • Kuskowski M.
        • et al.
        Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
        Eur J Heart Fail. 2013; 15: 511-518
        • Gullestad L.
        • Ueland T.
        • Kjekshus J.
        • et al.
        The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
        Am Heart J. 2012; 164: 878-883
        • Lok D.J.
        • Van Der Meer P.
        • de la Porte P.W.
        • et al.
        Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.
        Clin Res Cardiol. 2010; 99: 323-328
        • Felker G.M.
        • Fiuzat M.
        • Shaw L.K.
        • et al.
        Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.
        Circ Heart Fail. 2012; 5: 72-78
        • Motiwala S.R.
        • Szymonifka J.
        • Belcher A.
        • et al.
        Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
        Eur J Heart Fail. 2013; 15: 1157-1163
        • Lok D.J.
        • Lok S.I.
        • Bruggink-Andre de la Porte P.W.
        • et al.
        Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.
        Clin Res Cardiol. 2013; 102: 103-110
        • Tang W.H.
        • Shrestha K.
        • Shao Z.
        • et al.
        Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.
        Am J Cardiol. 2011; 108: 385-390
        • de Boer R.A.
        • Lok D.J.
        • Jaarsma T.
        • et al.
        Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.
        Ann Med. 2011; 43: 60-68
        • Lopez-Andres N.
        • Rossignol P.
        • Iraqi W.
        • et al.
        Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
        Eur J Heart Fail. 2012; 14: 74-81
        • Erkilet G.
        • Ozpeker C.
        • Bothig D.
        • et al.
        The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices.
        J Heart Lung Transplant. 2013; 32: 221-230